T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
26 Sep 2024
Historique:
received: 29 07 2024
revised: 12 09 2024
accepted: 18 09 2024
medline: 26 10 2024
pubmed: 26 10 2024
entrez: 26 10 2024
Statut: epublish

Résumé

COVID-19 remains a significant threat, particularly to vulnerable populations. The emergence of new variants necessitates the development of treatments and vaccines that induce both humoral and cellular immunity. This study aimed to identify potentially immunogenic SARS-CoV-2 peptides and to explore the intricate host-pathogen interactions involving peripheral immune responses, memory profiles, and various demographic, clinical, and lifestyle factors. Using in silico and experimental methods, we identified several CD8-restricted SARS-CoV-2 peptides that are either poorly studied or have previously unreported immunogenicity: fifteen from the Spike and three each from non-structural proteins Nsp1-2-3-16. A Spike peptide, LA-9, demonstrated a 57% response rate in ELISpot assays using PBMCs from 14 HLA-A*02:01 positive, vaccinated, and mild-COVID-19 recovered subjects, indicating its potential for diagnostics, research, and multi-epitope vaccine platforms. We also found that younger individuals, with fewer vaccine doses and longer intervals since infection, showed lower anti-Spike (ELISA) and anti-Wuhan neutralizing antibodies (pseudovirus assay), higher naïve T cells, and lower central memory, effector memory, and CD4hiCD8low T cells (flow cytometry) compared to older subjects. In our cohort, a higher prevalence of Vδ2-γδ and DN T cells, and fewer naïve CD8 T cells, seemed to correlate with strong cellular and lower anti-NP antibody responses and to associate with Omicron infection, absence of confusional state, and habitual sporting activity.

Identifiants

pubmed: 39456150
pii: biom14101217
doi: 10.3390/biom14101217
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Spike Glycoprotein, Coronavirus 0
Peptides 0
spike protein, SARS-CoV-2 0
Antibodies, Viral 0
Antibodies, Neutralizing 0
Epitopes, T-Lymphocyte 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Istituto Superiore di Sanità
ID : ISS/DON12/2021

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Iole Macchia (I)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Valentina La Sorsa (V)

Research Promotion and Coordination Service, Istituto Superiore di Sanità, 00161 Rome, Italy.

Alessandra Ciervo (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

Irene Ruspantini (I)

Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy.

Donatella Negri (D)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

Martina Borghi (M)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

Maria Laura De Angelis (ML)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Francesca Luciani (F)

National Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, 00161 Rome, Italy.

Antonio Martina (A)

National Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, 00161 Rome, Italy.

Silvia Taglieri (S)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Valentina Durastanti (V)

Neurology Unit, San Filippo Neri Hospital, ASL RM1, 00135 Rome, Italy.

Maria Concetta Altavista (MC)

Neurology Unit, San Filippo Neri Hospital, ASL RM1, 00135 Rome, Italy.

Francesca Urbani (F)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Fabiola Mancini (F)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH